메뉴 건너뛰기




Volumn 30, Issue 4, 2010, Pages 375-389

Ceftaroline: A new cephalosporin with activity against resistant gram-positive pathogens

Author keywords

Ceftaroline; Cephalosporin; Methicillin resistant staphylococcus aureus; MRSA; PPI 0903; PPI 0903M; T 91825; TAK 599

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; AZTREONAM; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE; CEFTAROLINE; CEFTAROLINE FOSAMIL; CEFTRIAXONE; CEPHALOSPORIN; CREATINE KINASE; LINEZOLID; PENICILLIN BINDING PROTEIN; PRODRUG; VANCOMYCIN;

EID: 77950436253     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.30.4.375     Document Type: Review
Times cited : (77)

References (61)
  • 1
    • 34548488202 scopus 로고    scopus 로고
    • Epidemiology of staphylococcal resistance
    • Shorr AF. Epidemiology of staphylococcal resistance. Clin Infect Dis 2007;45(suppl 3):S171-6.
    • (2007) Clin Infect Dis , vol.45 , Issue.3 SUPPL.
    • Shorr, A.F.1
  • 2
    • 31044456290 scopus 로고    scopus 로고
    • Changes in the epidemiology of methicillin-resistant Staphylococcus aureus in intensive care units in U.S. hospitals, 1992-2003
    • Klevens RM, Edwards JR, Tenover FC, McDonald LC, Horan T, Gaynes R. Changes in the epidemiology of methicillin-resistant Staphylococcus aureus in intensive care units in U.S. hospitals, 1992-2003. Clin Infect Dis 2006;42:389-391
    • (2006) Clin Infect Dis , vol.42 , pp. 389-391
    • Klevens, R.M.1    Edwards, J.R.2    Tenover, F.C.3    McDonald, L.C.4    Horan, T.5    Gaynes, R.6
  • 3
    • 44149101032 scopus 로고    scopus 로고
    • Increasing antibiotic resistance among methicillin-resistant Staphylococcus aureus strains
    • Sakoulas G, Moellering RC Jr. Increasing antibiotic resistance among methicillin-resistant Staphylococcus aureus strains. Clin Infect Dis 2008;46(suppl 5):S360-7.
    • (2008) Clin Infect Dis , vol.46 , Issue.5 SUPPL.
    • Sakoulas, G.1    Moellering Jr., R.C.2
  • 5
    • 68049093117 scopus 로고    scopus 로고
    • Increase in pneumococcus macrolide resistance, United States
    • Jenkins SG, Farrell DJ. Increase in pneumococcus macrolide resistance, United States. Emerg Infect Dis 2009;15:1260-1264
    • (2009) Emerg Infect Dis , vol.15 , pp. 1260-1264
    • Jenkins, S.G.1    Farrell, D.J.2
  • 6
    • 60649089374 scopus 로고    scopus 로고
    • Susceptibilites of Haemophilus influenzae, Streptococcus pneumoniae, including serotype 19A, and Moraxella catarrhalis paediatric isolates from 2005 to 2007 to commonly used antibiotics
    • Harrison CJ, Woods C, Stout G, Martin B, Selvarangan R. Susceptibilites of Haemophilus influenzae, Streptococcus pneumoniae, including serotype 19A, and Moraxella catarrhalis paediatric isolates from 2005 to 2007 to commonly used antibiotics. J Antimicrob Chemother 2009;63:511-519
    • (2009) J Antimicrob Chemother , vol.63 , pp. 511-519
    • Harrison, C.J.1    Woods, C.2    Stout, G.3    Martin, B.4    Selvarangan, R.5
  • 8
    • 34249906193 scopus 로고    scopus 로고
    • Counterpoint: Vancomycin and Staphylococcus aureus: an antibiotic enters obsolescence
    • Deresinski S. Counterpoint: vancomycin and Staphylococcus aureus: an antibiotic enters obsolescence. Clin Infect Dis 2007;44:1543-1548
    • (2007) Clin Infect Dis , vol.44 , pp. 1543-1548
    • Deresinski, S.1
  • 9
    • 50949085411 scopus 로고    scopus 로고
    • Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin
    • Lodise TP, Graves J, Evans A, et al. Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob Agents Chemother 2008;52:3315-3320
    • (2008) Antimicrob Agents Chemother , vol.52 , pp. 3315-3320
    • Lodise, T.P.1    Graves, J.2    Evans, A.3
  • 10
    • 39449112495 scopus 로고    scopus 로고
    • Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia
    • Soriano A, Marco F, Martinez JA, et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 2008;46:193-200.
    • (2008) Clin Infect Dis , vol.46 , pp. 193-200
    • Soriano, A.1    Marco, F.2    Martinez, J.A.3
  • 11
    • 34447278781 scopus 로고    scopus 로고
    • Vancomycin in vitro bactericidal activity and its relationship to efficacy in clearance of methicillin-resistant Staphylococcus aureus bacteremia
    • Moise PA, Sakoulas G, Forrest A, Schentag JJ. Vancomycin in vitro bactericidal activity and its relationship to efficacy in clearance of methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob Agents Chemother 2007;51:2582-2586
    • (2007) Antimicrob Agents Chemother , vol.51 , pp. 2582-2586
    • Moise, P.A.1    Sakoulas, G.2    Forrest, A.3    Schentag, J.J.4
  • 12
    • 33750285524 scopus 로고    scopus 로고
    • High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: Efficacy and toxicity
    • Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-Beringer A. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med 2006;166:2138-2144
    • (2006) Arch Intern Med , vol.166 , pp. 2138-2144
    • Hidayat, L.K.1    Hsu, D.I.2    Quist, R.3    Shriner, K.A.4    Wong-Beringer, A.5
  • 13
    • 2942558870 scopus 로고    scopus 로고
    • Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia
    • Sakoulas G, Moise-Broder PA, Schentag J, Forrest A, Moellering RC Jr, Eliopoulos GM. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol 2004;42:2398-2402
    • (2004) J Clin Microbiol , vol.42 , pp. 2398-2402
    • Sakoulas, G.1    Moise-Broder, P.A.2    Schentag, J.3    Forrest, A.4    Moellering Jr., R.C.5    Eliopoulos, G.M.6
  • 14
    • 12444281009 scopus 로고    scopus 로고
    • TAK-599, a novel N-phosphono-type prodrug of anti-MRSA cephalosporin T-91825: Synthesis, physicochemical and pharmacological properties
    • Ishikawa T, Matsunaga N, Tawada H, et al. TAK-599, a novel N-phosphono-type prodrug of anti-MRSA cephalosporin T-91825: synthesis, physicochemical and pharmacological properties. Bioorg Med Chem 2003;11:2427-2437
    • (2003) Bioorg Med Chem , vol.11 , pp. 2427-2437
    • Ishikawa, T.1    Matsunaga, N.2    Tawada, H.3
  • 15
    • 54349094745 scopus 로고    scopus 로고
    • Stability and stabilization studies of TAK-599 (ceftaroline fosamil), a novel N-phosphono-type prodrug of anti-methicillin-resistant Staphylococcus aureus cephalosporin T-91825
    • Ikeda Y, Ban J, Ishikawa T, Hashiguchi S, Urayama S, Horibe H. Stability and stabilization studies of TAK-599 (ceftaroline fosamil), a novel N-phosphono-type prodrug of anti-methicillin-resistant Staphylococcus aureus cephalosporin T-91825. Chem Pharm Bull 2008;56:1406-1411
    • (2008) Chem Pharm Bull , vol.56 , pp. 1406-1411
    • Ikeda, Y.1    Ban, J.2    Ishikawa, T.3    Hashiguchi, S.4    Urayama, S.5    Horibe, H.6
  • 16
    • 47749154496 scopus 로고    scopus 로고
    • Co-opting the cell wall in fighting methicillin-resistant Staphylococcus aureus: Potent inhibition of PBP2a by two anti-MRSA β-lactam antibiotics
    • Villegas-Estrada A, Lee M, Hesek D, Vakulenko SB, Mobashery S. Co-opting the cell wall in fighting methicillin-resistant Staphylococcus aureus: potent inhibition of PBP2a by two anti-MRSA β-lactam antibiotics. J Am Chem Soc 2008;130:9212-9213
    • (2008) J Am Chem Soc , vol.130 , pp. 9212-9213
    • Villegas-Estrada, A.1    Lee, M.2    Hesek, D.3    Vakulenko, S.B.4    Mobashery, S.5
  • 18
    • 23044471735 scopus 로고    scopus 로고
    • Antimicrobial activity and spectrum of PPI-0903M (T-91825), a novel cephalosporin, tested against a worldwide collection of clinical strains
    • Sader HS, Fritsche TR, Kaniga K, Ge Y, Jones RN. Antimicrobial activity and spectrum of PPI-0903M (T-91825), a novel cephalosporin, tested against a worldwide collection of clinical strains. Antimicrob Agents Chemother 2005;49:3501-3512
    • (2005) Antimicrob Agents Chemother , vol.49 , pp. 3501-3512
    • Sader, H.S.1    Fritsche, T.R.2    Kaniga, K.3    Ge, Y.4    Jones, R.N.5
  • 19
    • 50949105050 scopus 로고    scopus 로고
    • In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States
    • Ge Y, Biek D, Talbot GH, Sahm DF. In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States. Antimicrob Agents Chemother 2008;52:3398-3407
    • (2008) Antimicrob Agents Chemother , vol.52 , pp. 3398-3407
    • Ge, Y.1    Biek, D.2    Talbot, G.H.3    Sahm, D.F.4
  • 20
    • 64549135399 scopus 로고    scopus 로고
    • Activity of the new cephalosporin ceftaroline against bacteraemia isolates from patients with community-acquired pneumonia
    • Morrissey I, Ge Y, Janes R. Activity of the new cephalosporin ceftaroline against bacteraemia isolates from patients with community-acquired pneumonia. Int J Antimicrob Agents 2009;33:515-519
    • (2009) Int J Antimicrob Agents , vol.33 , pp. 515-519
    • Morrissey, I.1    Ge, Y.2    Janes, R.3
  • 21
    • 77950398872 scopus 로고    scopus 로고
    • Antimicrobial activity of ceftaroline tested against contemporary (2008) bacteria isolated from community-acquired respiratory tract infections (CARTI), including oxacillin- (methicillin-) resistant Staphylococcus aureus. Poster presentation at the
    • Sader HS, Jones RN. Antimicrobial activity of ceftaroline tested against contemporary (2008) bacteria isolated from community-acquired respiratory tract infections (CARTI), including oxacillin- (methicillin-) resistant Staphylococcus aureus. Poster presentation at the Staphylococcus symposium, Honolulu, HI, March 11-14, 2009.
    • Staphylococcus Symposium, Honolulu, HI, March 11-14, 2009
    • Sader, H.S.1    Jones, R.N.2
  • 23
    • 40549135961 scopus 로고    scopus 로고
    • Antimicrobial activities of ceftaroline and ME1036 tested against clinical strains of community-acquired methicillin-resistant Staphylococcus aureus
    • Sader HS, Fritsche TR, Jones RN. Antimicrobial activities of ceftaroline and ME1036 tested against clinical strains of community-acquired methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2008;52:1153-1155
    • (2008) Antimicrob Agents Chemother , vol.52 , pp. 1153-1155
    • Sader, H.S.1    Fritsche, T.R.2    Jones, R.N.3
  • 25
    • 55849104841 scopus 로고    scopus 로고
    • In vitro activity of ceftaroline against Streptococcus pneumoniae isolates exhibiting resistance to penicillin, amoxicillin, and cefotaxime
    • Fenoll A, Aguilar L, Robledo O, et al. In vitro activity of ceftaroline against Streptococcus pneumoniae isolates exhibiting resistance to penicillin, amoxicillin, and cefotaxime. Antimicrob Agents Chemother 2008;52:4209-4210
    • (2008) Antimicrob Agents Chemother , vol.52 , pp. 4209-4210
    • Fenoll, A.1    Aguilar, L.2    Robledo, O.3
  • 26
    • 59749096800 scopus 로고    scopus 로고
    • In vitro evaluation of the antimicrobial activity of ceftaroline against cephalosporin-resistant isolates of Streptococcus pneumoniae
    • McGee L, Biek D, Ge Y, et al. In vitro evaluation of the antimicrobial activity of ceftaroline against cephalosporin-resistant isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother 2009;53:552-556
    • (2009) Antimicrob Agents Chemother , vol.53 , pp. 552-556
    • McGee, L.1    Biek, D.2    Ge, Y.3
  • 29
    • 34547841550 scopus 로고    scopus 로고
    • In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes
    • Mushtaq S, Warner M, Ge Y, Kaniga K, Livermore DM. In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes. J Antimicrob Chemother 2007;60:300-311
    • (2007) J Antimicrob Chemother , vol.60 , pp. 300-311
    • Mushtaq, S.1    Warner, M.2    Ge, Y.3    Kaniga, K.4    Livermore, D.M.5
  • 34
    • 67049086953 scopus 로고    scopus 로고
    • In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including β-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa
    • Vidaillac C, Leonard SN, Sader HS, Jones RN, Rybak MJ. In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including β-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa. Antimicrob Agents Chemother 2009;53:2360-2366
    • (2009) Antimicrob Agents Chemother , vol.53 , pp. 2360-2366
    • Vidaillac, C.1    Leonard, S.N.2    Sader, H.S.3    Jones, R.N.4    Rybak, M.J.5
  • 36
    • 29444443515 scopus 로고    scopus 로고
    • Evaluation of PPI-0903M (T91825), a novel cephalosporin: Bactericidal activity, effects of modifying in vitro testing parameters and optimization of disc diffusion tests
    • Jones RN, Fritsche TR, Ge Y, Kaniga K, Sader HS. Evaluation of PPI-0903M (T91825), a novel cephalosporin: bactericidal activity, effects of modifying in vitro testing parameters and optimization of disc diffusion tests. J Antimicrob Chemother 2005;56:1047-1052
    • (2005) J Antimicrob Chemother , vol.56 , pp. 1047-1052
    • Jones, R.N.1    Fritsche, T.R.2    Ge, Y.3    Kaniga, K.4    Sader, H.S.5
  • 37
    • 62949159531 scopus 로고    scopus 로고
    • In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing
    • Brown SD, Traczewski MM. In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing. Antimicrob Agents Chemother 2009;53:1271-1274
    • (2009) Antimicrob Agents Chemother , vol.53 , pp. 1271-1274
    • Brown, S.D.1    Traczewski, M.M.2
  • 49
    • 33645766499 scopus 로고    scopus 로고
    • Pharmacodynamics of a new cephalosporin, PPI-0903 (TAK-599), active against methicillin-resistant Staphylococcus aureus in murine thigh and lung infection models: Identification of an in vivo pharmacokinetic-pharmacodynamic target
    • Andes D, Craig WA. Pharmacodynamics of a new cephalosporin, PPI-0903 (TAK-599), active against methicillin-resistant Staphylococcus aureus in murine thigh and lung infection models: identification of an in vivo pharmacokinetic-pharmacodynamic target. Antimicrob Agents Chemother 2006;50:1376-1383
    • (2006) Antimicrob Agents Chemother , vol.50 , pp. 1376-1383
    • Andes, D.1    Craig, W.A.2
  • 51
    • 3843081646 scopus 로고    scopus 로고
    • In vitro antimicrobial activity of T-91825, a novel anti-MRSA cephalosporin, and in vivo anti-MRSA activity of its prodrug, TAK-599
    • Iizawa Y, Nagai J, Ishikawa T, et al. In vitro antimicrobial activity of T-91825, a novel anti-MRSA cephalosporin, and in vivo anti-MRSA activity of its prodrug, TAK-599. J Infect Chemother 2004;10:146-156
    • (2004) J Infect Chemother , vol.10 , pp. 146-156
    • Iizawa, Y.1    Nagai, J.2    Ishikawa, T.3
  • 55
    • 35948962693 scopus 로고    scopus 로고
    • In vivo efficacy of ceftaroline (PPI-0903), a new broad-spectrum cephalosporin, compared with linezolid and vancomycin against methicillin-resistant and vancomycin-intermediate
    • Jacqueline C, Caillon J, Le Mabecque V, et al. In vivo efficacy of ceftaroline (PPI-0903), a new broad-spectrum cephalosporin, compared with linezolid and vancomycin against methicillin-resistant and vancomycin- intermediate Staphylococcus aureus in a rabbit endocarditis model. Antimicrob Agents Chemother 2007;51:3397-3400
    • (2007) Staphylococcus Aureus in a Rabbit Endocarditis Model. Antimicrob Agents Chemother , vol.51 , pp. 3397-3400
    • Jacqueline, C.1    Caillon, J.2    Le Mabecque, V.3
  • 57
    • 34948854764 scopus 로고    scopus 로고
    • Phase 2 study of ceftaroline versus standard therapy in treatment of complicated skin and skin structure infections
    • Talbot GH, Thye D, Das A, Ge Y. Phase 2 study of ceftaroline versus standard therapy in treatment of complicated skin and skin structure infections. Antimicrob Agents Chemother 2007;51:3612-3616
    • (2007) Antimicrob Agents Chemother , vol.51 , pp. 3612-3616
    • Talbot, G.H.1    Thye, D.2    Das, A.3    Ge, Y.4
  • 60
    • 77950431697 scopus 로고    scopus 로고
    • U.S. National Institutes of Health. Available from Accessed November 23, 2009
    • U.S. National Institutes of Health. ClinicalTrials.gov. Available from http://clinicaltrials.gov/ct2/results?term=ceftaroline. Accessed November 23, 2009.


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.